TIDMMEDG TIDMMEDU
RNS Number : 2065V
Medgenics Inc
09 January 2013
Press Release 9 January 2013
Medgenics, Inc.
(the "Company")
Block Listing Interim Review
1. Name of company:
Medgenics, Inc.
2. Name of scheme:
Warrants, Options and Restricted Shares under the Company's
Share Incentive Schemes
3. Period of return:
From To
------------ ---------------
6 July 2012 5 January 2013
------------ ---------------
4. Number and class of securities not issued under the scheme at
the beginning of the period:
(i) MEDG TIDM - 923,054 common shares of par value of US$0.0001
each ("Common Shares") Regulation S restrictions, ISIN USU582411158
("Reg S"); and
(ii) MEDU TIDM - 912,899 Common Shares ISIN US58436Q2030
5. Number of securities issued under scheme during period:
(i) MEDG TIDM (Reg. S) - 232,739 Common Shares following the due
exercise of Warrants, Options and Restricted Shares issued by the
Company
(ii) MEDU TIDM - 363,818 Common Shares following the due
exercise of Warrants and Options issued by the Company
6. Balance under scheme of securities not yet issued at end of
period:
(i) MEDG TIDM (Reg. S) - 690,315 Common Shares
(ii) MEDU TIDM - 549,081 Common Shares
7. Number and class of securities originally admitted and the
date of admission:
(i) MEDG TIDM (Reg. S) - 963,119 Common Shares (6 July 2011)
(ii) MEDU TIDM - 963,119 Common Shares (6 July 2011).
Following the above issues during the period the total number of
Common Shares in issue is 12,342,808. The percentage of shares not
in public hands is 24.7 per cent.
For further information, contact:
Medgenics, Inc. Phone: +972 4 902 8900
Dr. Andrew L. Pearlman
Andrew.pearlman@medgenics.com
Abchurch Communications Phone: +44 207 398 7719
Adam Michael
Joanne Shears
Jamie Hooper
jamie.hooper@abchurch-group.com
SVS Securities plc (Joint Broker) Phone: +44 207 638 5600
Alex Mattey
Ian Callaway
Nomura Code Securities (NOMAD/Broker) Phone: +44 207 776 1219
Jonathan Senior
Giles Balleny
About Medgenics
Medgenics is developing and commercializing Biopump(TM), a
proprietary tissue-based platform technology for the sustained
production and delivery of therapeutic proteins using the patient's
own tissue for the treatment of a range of chronic diseases
including anemia, hepatitis and hemophilia, among others. Medgenics
believes this approach has multiple benefits compared with current
treatments, which include regular and costly injections of
therapeutic proteins.
Medgenics has three long-acting protein therapy products in
development based on this technology:
-- EPODURE(TM) to produce and deliver erythropoietin from a
single administration, which has demonstrated elevation and
stabilization of hemoglobin levels in anemic patients for periods
of six months to more than 36 months in a Phase I/II dose-ranging
trial in Israel and is currently in a Phase IIa trial in dialysis
in Israel. An Investigational New Drug application has been cleared
by the FDA to initiate a Phase IIb study to evaluate the safety and
efficacy of EPODURE in the treatment of anemia in dialysis patients
in the U.S., expected to launch in H2 2013.
-- INFRADURE(TM) for sustained production and delivery of
interferon-alpha for use in the treatment of hepatitis, which has
received approval for two Phase I/II trials in hepatitis C from the
Israeli Ministry of Health with the first slated to commence in
2013; and has received Orphan Drug Designation from the FDA for the
treatment of hepatitis D.
-- HEMODURE(TM) for sustained production and delivery of
clotting Factor VIII therapy for the sustained prophylactic
treatment of hemophilia, which is now in development.
Medgenics is focused on the development and manufacturing of its
innovative Biopumps, aiming to bring them to market via strategic
partnerships with major pharmaceutical and/or medical device
companies.
In addition to treatments for anemia, hepatitis and hemophilia,
Medgenics plans to develop and/or out-license a pipeline of future
Biopump products targeting the large and rapidly growing global
protein therapy market, which is forecast to reach $132 billion in
2013. Other potential applications for Biopumps include multiple
sclerosis, arthritis, pediatric growth hormone deficiency, obesity
and diabetes.
Forward-looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and as that term is defined
in the Private Securities Litigation Reform Act of 1995, which
include all statements other than statements of historical fact,
including (without limitation) those regarding the Company's
financial position, its development and business strategy, its
product candidates and the plans and objectives of management for
future operations. The Company intends that such forward-looking
statements be subject to the safe harbors created by such laws.
Forward-looking statements are sometimes identified by their use of
the terms and phrases such as "estimate," "project," "intend, "
"forecast," "anticipate," "plan," "planning, "expect," "believe,"
"will," "will likely," "should," "could," "would," "may" or the
negative of such terms and other comparable terminology. All such
forward-looking statements are based on current expectations and
are subject to risks and uncertainties. Should any of these risks
or uncertainties materialize, or should any of the Company's
assumptions prove incorrect, actual results may differ materially
from those included within these forward-looking statements.
Accordingly, no undue reliance should be placed on these
forward-looking statements, which speak only as of the date made.
The Company expressly disclaims any obligation or undertaking to
disseminate any updates or revisions to any forward-looking
statements contained herein to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based.
As a result of these factors, the events described in the
forward-looking statements contained in this release may not
occur.
-ENDS-
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLMFTMBTMBMJ
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From May 2024 to Jun 2024
Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart
From Jun 2023 to Jun 2024
